---
title: "BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299164659.md"
description: "BTIG reiterated a Buy rating on Nektar Therapeutics with a $178 price target, implying a 167.1% upside from the September 15 close of $66.64. The firm cites a strong pipeline of immunomodulatory agents for autoimmune diseases and cancer, positive Phase 2 trial progress for rezpegaldesleukin in atopic dermatitis and alopecia areata, and the initiation of multiple Phase 3 trials as key drivers for potential growth and commercialization."
datetime: "2026-09-16T10:05:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299164659.md)
  - [en](https://longbridge.com/en/news/299164659.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299164659.md)
generator: "portal-rs"
---

# BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target

BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00.

The price target implies an upside of 167.1% from the Sep 15 close of $66.64.

**Key takeaways from the analyst note**

**Strong Pipeline of Immunomodulatory Agents**: Nektar Therapeutics is focused on developing a diverse portfolio of immunomodulatory therapies aimed at treating autoimmune diseases and cancer, which positions the company favorably for potential growth in the biopharmaceutical market.

**Positive Phase 2 Trial Progress**: The advancement of Nektar's lead program, rezpegaldesleukin, through Phase 2 trials for atopic dermatitis and alopecia areata, along with the initiation of multiple Phase 3 trials, indicates promising clinical progress that could lead to commercialization and revenue generation.

Explore more price target data and ratings for Nektar Therapeutics on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [NKTR.US](https://longbridge.com/en/quote/NKTR.US.md)

## Related News & Research

- [Nektar Therapeutics (NKTR) Draws Fresh Eczema Buzz Following A 72% Undervalued Narrative](https://longbridge.com/en/news/304724903.md)
- [What Nektar Therapeutics Stock's Late Stage Eczema Drug Progress Means For Shareholders](https://longbridge.com/en/news/304756413.md)
- [KTA: Profitability improved, but weaker demand and unresolved 2027 refinancing keep risks elevated](https://longbridge.com/en/news/304985171.md)
- [Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine](https://longbridge.com/en/news/305169520.md)
- [OXY: Strong Q3 cash generation advanced debt reduction and the >$4B annual cash flow goal by 2030](https://longbridge.com/en/news/305061493.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**